Sanofi to Focus on Increasing Prescriptions of Lantus XR Based on Results of Head-to-Head Comparison Study

Since data from a clinical trial showed a lower rate of hypoglycemic events with Lantus XR Injection SoloStar (insulin glargine) compared to insulin degludec during the first 12 weeks after starting insulin therapy, Sanofi will focus on increasing prescriptions of...read more